Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice.

Clinical and experimental medicine - 20 Apr 2024

van Kooten Job P, Dietz Michelle V, Dubbink Hendrikus Jan, Verhoef Cornelis, Aerts Joachim G J V, Madsen Eva V E, von der Thüsen Jan H

Abstract excerpt

Peritoneal mesothelioma (PeM) is an aggressive tumor with limited treatment options. The current study aimed to evaluate the value of next generation sequencing (NGS) of PeM samples in current practice. Foundation Medicine F1CDx NGS was performed on 20 tumor samples. This platform assesses 360 commonly somatically mutated genes in solid tumors and provides a genomic signature. Based on the detected mutations,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Genomics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mesothelioma

Share to Mesothelioma, Malignant

Share to Mutation

Share to Peritoneal Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38642130
DOI: 10.1007/s10238-024-01342-y
PMCID: PMC11032274

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice.PMID 38642130Read ↗

Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies.Semantic proximity Read ↗

Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesotheliomaSemantic proximity Read ↗

Genomic Landscape of Malignant Mesotheliomas.Semantic proximity Read ↗

Personalized Oncogenomics: Clinical Experience with Malignant Peritoneal Mesothelioma Using Whole Genome SequencingSemantic proximity Read ↗

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesotheliomaSemantic proximity Read ↗

BAP1 Loss Predicts Therapeutic Vulnerability in Malignant Peritoneal MesotheliomaSemantic proximity Read ↗

Inactivation of BAP1 and the Hippo Pathway Defines the Mutational Landscape of Peritoneal MesotheliomaSemantic proximity Read ↗

Gender differences in molecular-guided therapy recommendations for metastatic malignant mesothelioma.Semantic proximity Read ↗

Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.Semantic proximity Read ↗

Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors.Semantic proximity Read ↗

Molecular profiling and personalized medicine within EURACAN in the SPECTA Arcagen study in comparison to the France Genomic Medicine 2025 Plan in the AURAGEN platform in peritoneal mesotheliomasSemantic proximity Read ↗

Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.